LNAI
HEALTHCARELunai Bioworks Inc.
AI Insight
What's Moving LNAI Today?
No stock-specific AI insight has been generated for LNAI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.21$29.60
$4.30
Fundamentals
Market Cap$21M
P/E Ratio—
EPS$-61.52
Dividend Yield—
Dividend / Share—
ROE-325.5%
Profit Margin—
Debt / Equity—
Trading
Volume297K
Avg Volume (10D)—
Shares Outstanding4.5M
LNAI News
27 articles- [8-K] Lunai Bioworks Inc. Reports Material EventStock Titan·Jun 17, 2026
- LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERSYahoo Finance·Jun 17, 2026
- Why Did LNAI Stock Soar Over 100% In Pre-Market Trading Today?Stocktwits·Jun 17, 2026
- Trending Stocks Today | Lunai Bioworks Surges 151.66% Pre-MarketMoomoo·Jun 17, 2026
- Lunai regains Nasdaq $1.00 bid-price compliance; one-year Panel monitoring imposedTradingView·Jun 16, 2026
- Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery CollaborationYahoo Finance·May 28, 2026
- Lunai Bioworks, Inc. Financial Disclosures & SEC FilingsTradingView·May 24, 2026
- LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLITYahoo Finance·May 20, 2026
- Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common StockThe Manila Times·May 12, 2026
- Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common StockGlobeNewswire Inc.·May 12, 2026
- Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s DiseaseYahoo Finance·May 6, 2026
- Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IPYahoo Finance·May 4, 2026
- Stock Market Today: Dow Jones, S&P 500 Futures Edge Lower Amid Extension Of Israel-Lebanon Ceasefire—Intel, SAP, Lunai Bioworks In FocusBenzinga·Apr 24, 2026
- Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma PartnershipsYahoo Finance·Apr 15, 2026
- Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under DiscussionBenzinga·Apr 7, 2026
- BC-Most Active StocksYahoo Finance·Mar 26, 2026
- Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery ApplicationsYahoo Finance·Mar 26, 2026
- Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development ModelYahoo Finance·Mar 19, 2026
- Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease SubtypingYahoo Finance·Feb 19, 2026
- Lunai Bioworks: Fiscal Q2 Earnings SnapshotYahoo Finance·Feb 17, 2026
- Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBCYahoo Finance·Feb 13, 2026
- Lunai Bioworks, Inc. Issues Letter to ShareholdersYahoo Finance·Feb 9, 2026
- Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial DataYahoo Finance·Feb 9, 2026
- Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical WeaponsYahoo Finance·Jan 27, 2026
- Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug DiscoveryYahoo Finance·Jan 26, 2026
- Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks AdvanceYahoo Finance·Dec 18, 2025
- Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B MarketYahoo Finance·Dec 9, 2025
All 27 articles loaded
Price Data
Open$3.99
Previous Close$4.30
Day High$4.78
Day Low$3.93
52 Week High$29.60
52 Week Low$1.21
52-Week Range
$1.21$29.60
$4.30
Fundamentals
Market Cap$21M
P/E Ratio—
EPS$-61.52
Dividend Yield—
Dividend / Share—
ROE-325.5%
Profit Margin—
Debt / Equity—
Trading
Volume297K
Avg Volume (10D)—
Shares Outstanding4.5M
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. The company is headquartered in Los Angeles, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—